作者
Ariel Izcovich, Reed Alexander Siemieniuk, Jessica Julia Bartoszko, Long Ge, Dena Zeraatkar, Elena Kum, Anila Qasim, Assem M Khamis, Bram Rochwerg, Thomas Agoritsas, Derek K Chu, Shelley L McLeod, Reem A Mustafa, Per Vandvik, Romina Brignardello-Petersen
发表日期
2022/3/1
来源
BMJ open
卷号
12
期号
3
页码范围
e048502
出版商
British Medical Journal Publishing Group
简介
Background
To summarise specific adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir in patients with COVID-19.
Methods
We searched 32 databases through 27 October 2020. We included randomised trials comparing any of the drugs of interest to placebo or standard care, or against each other. We conducted fixed-effects pairwise meta-analysis and assessed the certainty of evidence using the grading of recommendations assessment, development and evaluation approach.
Results
We included 16 randomised trials which enrolled 8152 patients. For most interventions and outcomes the certainty of the evidence was very low to low except for gastrointestinal adverse effects from hydroxychloroquine, which was moderate certainty. Compared with standard care or placebo, low certainty evidence suggests that remdesivir may not have an important effect on acute kidney injury (risk difference …
学术搜索中的文章
A Izcovich, RA Siemieniuk, JJ Bartoszko, L Ge… - BMJ open, 2022